Ghost Tree Capital’s Catalyst Pharmaceutical CPRX Stock Holding History

Ghost Tree Capital’s Portfolio CPRX Stock Details CPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q4	–	Sell	-100,000	Closed	-$332K	–	68
2014 Q3	$332K	Buy	+100,000	New	+$261K	0.18%	67

Other funds holding CPRX

Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

CCM

Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Ghost Tree Capital's CPRX Position: Q2 2018 in Review

Ghost Tree Capital sold out of Catalyst Pharmaceutical (CPRX) in Q2 2018, closing a stake of 550,000 shares — an estimated $1.31M sold.

Ghost Tree Capital first reported a position in CPRX in Q4 2013 and held it in 8 quarters. The position peaked at $2.15M in Q4 2017. 99 funds tracked by Wall St. Rank hold CPRX as of Q2 2018.

Ghost Tree Capital reported no remaining Catalyst Pharmaceutical position as of Q2 2018 after selling out during the quarter.
Ghost Tree Capital sold 550,000 Catalyst Pharmaceutical shares in Q2 2018, an estimated $1.31M.
Ghost Tree Capital first reported a position in Catalyst Pharmaceutical in Q4 2013 and held it in 8 quarters.
Ghost Tree Capital's Catalyst Pharmaceutical position peaked at $2.15M in Q4 2017.
99 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q2 2018.

Based on Ghost Tree Capital's 13F filing for Q2 2018, filed 14 Aug 2018.